Akamis Bio

UK- and US-based Akamis Bio (previously known as PsiOxus) is a developer of therapeutics used to treat cancer by using gene therapy platforms. The company develops tumor-specific therapeutics and is curating a library of Tumor-Specific Immuno-Gene (T-SIGn) therapeutics that help a patient’s immune system recognize, attack, and clear cancer cells. Akamis is developing its T-SIGn therapeutics in such a way that the company claims it can enhance the effectiveness of other cell-based therapeutics such as chimeric antigen receptor T-cell (CAR-T)-based therapies.

As of May 2024, the company had one therapeutic using CD40 agonistic platforms for tumor-specific targeting called NG-350A in Phase I of clinical trials. Akamis had another therapeutic candidate using T-cell and Natural Killer cell activation (NK) for tumor-specific targeting called NG-7xx in investigational new drug application (IND)-enabling stage of clinical trials. Akamis was also developing a therapeutic using CAR-T cell targeting and activation for specific tumor-targeting for an undisclosed party. The solution was in the research stages.

Key customers and partnerships

Akamis has listed several collaborations that it has carried out with other pharmaceutical providers such as Bristol Myers Squibb, Dana-Farber Cancer Institute, MSD, and the University of Oxford.

Further to the above, the company partnered with the Parker Institute for Cancer Immunotherapy (PICI) and Cancer Research Institute (CRI) in January 2023 to assess Akamis’ cancer therapeutics. Through the partnership, PICI and CRI would assess Akamis’ therapeutic candidates NG-350A and CTLA-4.